Prostate Volume and Pathologic Prostate Cancer Outcomes After Radical Prostatectomy

Urology

Volumn 70, Issue 4, 2007, Pages 696-701

  Pierorazio, Phillip M ^a   Kinnaman, Michael D ^a   Wosnitzer, Matthew S ^a   Benson, Mitchell C ^a   McKiernan, James M ^a   Goluboff, Erik T ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER STAGING; CANCER SURGERY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY;

AGED; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 35648947843     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.05.022     Document Type: Article

References (29)

1. Benson M.C., Whang I.S., Olsson C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147 (1992) 817-821
2. Benson M.C., Whang I.S., Pantuck A., et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147 (1992) 815-816
3. Eskicorapci S.Y., Guliyev F., Akdogan B., et al. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 173 (2005) 1536-1540
4. Carter H.B., Walsh P.C., Landis P., et al. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 167 (2002) 1231-1234
5. Warlick C.A., Allaf M.E., and Carter H.B. Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. Urol Oncol 24 (2006) 51-57
6. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
7. Steyerberg E.W., Roobol M.J., Kattan M.W., et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 177 (2007) 107-112
8. Carter H.B., Sauvageot J., Walsh P.C., et al. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 157 (1997) 2206-2209
9. Epstein J.I., Chan D.W., Sokoll L.J., et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160 (1998) 2407-2411
10. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
11. Goto Y., Ohori M., Arakawa A., et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156 (1996) 1059-1063
12. Karakiewicz P.I., Bazinet M., Aprikian A.G., et al. Outcome of sextant biopsy according to gland volume. Urology 49 (1997) 55-59
13. Uzzo R.G., Wei J.T., Waldbaum R.S., et al. The influence of prostate size on cancer detection. Urology 46 (1995) 831-836
14. Chen M.E., Troncoso P., Johnston D., et al. Prostate cancer detection: relationship to prostate size. Urology 53 (1999) 764-768
15. Catalona W.J., Stein A.J., and Fair W.R. Grading errors in prostatic needle biopsies: relation to the accuracy of tumor grade in predicting pelvic lymph node metastases. J Urol 127 (1982) 919-922
16. Garnett J.E., Oyasu R., and Grayhack J.T. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. J Urol 131 (1984) 690-693
17. Tannenbaum M., Tannenbaum S., deSanctis P.N., et al. Prognostic significance of nucleolar surface area in prostate cancer. Urology 19 (1982) 546-551
18. Letran J.L., Meyer G.E., Loberiza F.R., et al. The effect of prostate volume on the yield of needle biopsy. J Urol 160 (1998) 1718-1721
19. Hammerer P.G., McNeal J.E., and Stamey T.A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 153 (1995) 111-114
20. De Marzo A.M., Coffey D.S., and Nelson W.G. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53 (1999) 29-42
21. Luo J., Duggan D.J., Chen Y., et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 61 (2001) 4683-4688
22. Stamey T.A., Warrington J.A., Caldwell M.C., et al. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166 (2001) 2171-2177
23. Prakash K., Pirozzi G., Elashoff M., et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA 99 (2002) 7598-7603
24. Bostwick D.G. Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18 (1994) 796-803
25. Hsieh T.F., Chang C.H., Chen W.C., et al. Correlation of Gleason scores between needle-core biopsy and radical prostatectomy specimens in patients with prostate cancer. J Chin Med Assoc 68 (2005) 167-171
26. Spires S.E., Cibull M.L., Wood Jr. D.P., et al. Gleason histologic grading in prostatic carcinoma: correlation of 18-gauge core biopsy with prostatectomy. Arch Pathol Lab Med 118 (1994) 705-708
27. Dalkin B.L., Ahmann F.R., and Kopp J.B. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150 (1993) 1837-1839
28. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
29. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771